Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

United Nations Makes Recommendation Not To Schedule CBD as Drug After Medical Marijuana, Inc. Executive Spoke at World Health Organization Convention

Medical Marijuana,Inc.
Posted on: 14 Dec 17
United Nations Makes Recommendation Not To Schedule CBD as Drug After Medical Marijuana, Inc. Executive Spoke at World Health Organization Convention HempMeds® Mexico President Raúl Elizalde Influences Global Policy Recommendation

PR Newswire

SAN DIEGO, Dec. 14, 2017

SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that the World Health Organization has made the expert recommendation not to schedule cannabidiol (CBD) as a drug. See statement here: http://www.who.int/medicines/news/2017/WHO-recommends-most-stringent-level-int-control/en/.

This news comes after subsidiary HempMeds® Mexico President Raúl Elizalde spoke on behalf of the family of companies to the U.N. at the World Health Organization's (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence on November 6, 2017.

There, Elizalde, a world-renowned medical cannabis advocate, spoke to international leaders about his daughter's personal experience with CBD and urged organization leaders to not consider CBD psychoactive and not schedule it as a drug. Elizalde also presented research findings from studies conducted with children using CBD hemp oil products in Mexico by Dr. Saul Garza and Dr. Carlos Aguirre.

In a statement by the World Health Organization, the Expert Committee on Drug Dependence has concluded:

"Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions. Current evidence also shows that cannabidiol is not likely to be abused or create dependence as for other cannabinoids (such as Tetra Hydro Cannabinol (THC), for instance). The ECDD therefore concluded that current information does not justify scheduling of cannabidiol and postponed a fuller review of cannabidiol preparations to May 2018, when the committee will undertake a comprehensive review of cannabis and cannabis related substances." 

"We couldn't have asked for a better outcome and we are thankful that Raul was able to play such a vital role in the World Health Organization's decision," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We hope that this recommendation makes it easier for people around the world to gain necessary access to CBD and improve their quality of life."

"We're ecstatic that these international health leaders agree that CBD is a substance that should not be scheduled and has therapeutic value for a variety of medical conditions," said HempMeds® Mexico President Raul Elizalde. "We look forward to continuing our conversation about CBD's many benefits in 2018." 

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.  This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.  The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.  The Company does sell and distribute hemp-based products.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

 

View original content:http://www.prnewswire.com/news-releases/united-nations-makes-recommendation-not-to-schedule-cbd-as-drug-after-medical-marijuana-inc-executive-spoke-at-world-health-organization-convention-300571242.html

SOURCE Medical Marijuana, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 14/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.